Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Teva Upbeat On Partnered Biosimilars With EU Ranibizumab Set For 2022

‘We Are Addressing Some 80% Of The Value Going Off-Patent In The Coming Years’

Executive Summary

Teva is confident that its partnered biosimilar programs – roughly half of its pipeline – will not dilute its margins, as it gears up to launch a biosimilar Lucentis product in the EU this year while pushing through other allied and internal assets in the US.

You may also be interested in...

Xbrane’s Ranibizumab Marches On With US FDA Filing Imminent

With Samsung Bioepis already holding US and EU approvals for biosimilar ranibizumab, Swedish sponsor Xbrane Biopharma says 12-month Phase III data supports ongoing registration of the Lucentis rival in both regions.

Leaner Teva Bolsters Margins With 2022 Expected To Be Trough Year

Keeping a keen eye on costs through a multi-pronged strategy allowed Teva to bolster its margins and direct cash flow towards debt in 2021. But revenues declined and 2022 is set to be another bumpy year for the Israeli giant’s top line.

Alvotech Suffers Delay On Higher-Strength Adalimumab In US

Alvotech has suffered a setback in its attempt to gain the first US FDA approval for a higher-strength biosimilar adalimumab rival to Humira, after obstacles preventing facility inspections led the agency to defer action on the firm’s AVT02 candidate.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts